Melissa Amrein, at the University Hospital of Basel, Switzerland, is awarded the 2021 Novelties in Biomarkers prize at the Biomarkers of the Future Conference in Paris, France

Rhea-AI Summary

Olink Holding AB (Nasdaq: OLK) announced the winner of the Novelties in Biomarkers award, Melissa Amrein from the University Hospital of Basel, during the Biomarkers of the Future conference in Paris. This annual award, established in 2019, aims to promote young researchers in biomarker discovery. This year witnessed a record number of submissions, with the winning abstract focusing on Gut microbiota-dependent metabolite trimethylamine N-oxide in patients with coronary artery disease. The conference also highlights the significance of high-throughput targeted proteomics in major disease research.

Positive

• Record number of submitted abstracts indicates growing interest in biomarker research.
• Recognition of innovative research supports brand credibility and engagement with the scientific community.

Negative

• None.

UPPSALA, Sweden, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) is proud to announce the winner of the young researchers’ award, Novelties in Biomarkers, Melissa Amrein at the University Hospital of Basel, Switzerland at the Biomarkers of the Future conference in Paris, France.

Novelties in Biomarkers is an annual award established in 2019 and supported by Olink Proteomics with the purpose of encouraging and motivating young scientists in their research in biomarker discovery.

This year the number of submitted abstracts was an all-time high, with participants representing different nationalities and continents. The theme of this year’s winning abstract was: Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) in patients with suspected functionally relevant coronary artery disease.

The prize committee’s members were Professor Alexandre Mebazaa, Chair of the meeting (Paris, France), Professor Pierre-François Laterre (Brussels, Belgium), Doctor Jane-Lise Samuel, chair of the Jury (Paris, France), Doctor Claude Delcayre, Doctor Benjamin Deniau and Professor Karen Sliwa (Cape Town, South Africa) representing the scientific committee.

“I am delighted to see the increasing interest and the high quality of the research that was submitted to the prize committee. For young fellow scientists, the conference and the competition are great opportunities to interact with senior researchers who represent a broad field of different disease areas alongside institutional and industry partners. The prize can also be a door-opener to help young scientists to highlight their research findings in distinguished publications,” says Professor Alexandre Mebazaa, vice-dean for international affairs at the faculty of health department of the Université de Paris, Head of anesthesia and critical care of the Saint Louis-Lariboisière - Fernand Widal University Hospitals and Director of Inserm-MASCOT research group.

“With this prize we want to encourage young, upcoming researchers to explore the possibilities of proteomics for biomarker discovery and to create a forum to share experiences and ideas. We enable them to build the research communities of the future,” says Andrea Ballagi, MD. Ph.D. MBA, Vice President Sales and Marketing, Olink Proteomics.

The Biomarker of the Future conference brings together international key opinion leaders along with young fellows, senior researchers, and industry partners, all focusing on biomarker discovery and research. The meeting is directed to the application of high-throughput targeted proteomics as a key tool to understand biology and pathophysiology, as well as identify protein biomarkers for early diagnosis and progression of major complex diseases.

The conference is supported by Olink Proteomics and Roche. The institutional partners are Université de Paris, Institut de science cardiovasculaire, Institut national de la santé et de la recherche médicale (Inserm), Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists (INI-CRCT), GREAT Association (Global research on acute conditions team).

More details are available on: Biomarkers of the Future

For more information please contact:

IR Contact
Jan Medina, CFA, VP Investor Relations & Capital Markets, Olink
Mobile: +1 617 802 4157
jan.medina@olink.com

Media Contact
Andrea Prander, Corporate Communications Manager, Olink
Mobile: + 46 768 775 275
andrea.prander@olink.com  

About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

FAQ

What is the significance of the Novelties in Biomarkers award announced by Olink (OLK)?

The Novelties in Biomarkers award encourages young researchers in biomarker discovery, showcasing innovative research and enhancing the scientific community's engagement.

What research topic won the Novelties in Biomarkers award in 2021?

The winning research topic was focused on the gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) in patients with suspected coronary artery disease.

Where was the Biomarkers of the Future conference held in 2021?

The Biomarkers of the Future conference took place in Paris, France.

How does Olink (OLK) support young researchers?

Olink supports young researchers through the Novelties in Biomarkers award, providing opportunities for exposure and collaboration within the scientific community.